Obesity and Metabolic Disorders

Obesity-Related Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)

NAFLD and its progressive form, non-alcoholic steatohepatitis (NASH), represent critical hepatic complications of obesity. Excess fat deposition in the liver leads to inflammation, fibrosis, and potential cirrhosis. Pathophysiological drivers include insulin resistance, dyslipidemia, and oxidative stress. NAFLD is strongly associated with cardiometabolic diseases, making early diagnosis essential. Imaging, biomarkers, and liver biopsy remain diagnostic tools, while weight reduction remains the cornerstone of management. Novel pharmacological agents targeting inflammation, fibrosis, and metabolic regulation are under development, holding potential for effective disease modification.